PhaseBio Pharmaceuticals, Inc. PHASQ OTC

PhaseBio Pharmaceuticals, Inc. (PHASQ) generated $-47.42M in operating cash flow for fiscal year 2021. After capital expenditures of $2.68M, free cash flow was $-50.1M.

Free cash flow margin was -462515% of revenue. Cash conversion ratio was 361.76x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (46/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 361.76x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 30/100 with 0/7 criteria passed.